Improving Treatment-Related Symptom Management in Adolescents and Young Adults

University of California, Davis1 site in 1 country20 target enrollmentSeptember 30, 2021

ConditionsCancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Cancer
Sponsor: University of California, Davis
Enrollment: 20
Locations: 1
Primary Endpoint: Proportion of Patients Completing the Trial
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study will test the acceptability and feasibility of a telehealth intervention to improve communication between patients and medical providers in adolescent and young adult (AYA) cancer patients receiving chemotherapy treatment.

Registry

clinicaltrials.gov

Start Date

September 30, 2021

End Date

December 31, 2023

Last Updated

last year

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

University of California, Davis

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with cancer undergoing active treatment and who have received at least two cycles of chemotherapy
•Access to Epic MyChart (we will facilitate access to MyChart for interested patients who are not yet signed up)
•Access to a smartphone or tablet to access EPIC MyChart telehealth appointments

Exclusion Criteria

•Non-English or non-Spanish speaking patients
•Potentially completing therapy during study period (including follow-up period) or plans to leave UCDCCC during study period

Outcomes

Primary Outcomes

Proportion of Patients Completing the Trial

Time Frame: end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days)

\>65% of enrolled patients will complete the trial

Secondary Outcomes

Survey Response Rate(end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days))
Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)(end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days))